63% of medical cannabis users with rheumatic conditions substituted it for other medications

62.5% substituted medical cannabis for medications: NSAIDs (54.7%), opioids (48.6%), sleep aids (29.6%), muscle relaxants (25.2%). Substitution was associated with THC use, inhalation routes, and significantly higher symptom improvements (pain, sleep, anxiety, joint stiffness). Most reported decreased or ceased medication use after substitution.

Secondary analysis of cross-sectional survey conducted with US and Canadian patient advocacy groups. 763 participants with rheumatic conditions using medical cannabis, compared substitution vs. non-substitution groups.

Nearly half of rheumatic disease patients who substituted were replacing opioids, a significant finding given the opioid crisis. Understanding substitution patterns helps clinicians anticipate and manage medication transitions.

The finding that substitutors reported higher symptom improvements may reflect selection bias (those who benefit substitute more), but it also suggests that for a subgroup of rheumatic disease patients, cannabis may address symptoms that conventional medications do not adequately manage.

Cross-sectional survey cannot establish causation. Self-selected sample from advocacy groups. Self-reported medication changes. Cannot verify actual medication reductions. Substitution may reflect dissatisfaction with previous medications rather than cannabis efficacy.